Abstract 5160
Background
The Irish Cancer Society is committed to monitoring the impact of our Cancer Information Services (CIS) at 4 key stages (prevention, support, survivorship and palliative) to demonstrate the positive changes our services bring to the people affected by cancer. CIS incorporates Cancer Nurseline (freephone cancer helpline) and Daffodil Centres (walkin cancer information and support centres) based in cancer centres. Both are staffed by specialist cancer nurses. CIS provides support, advice and information to anyone affected by cancer. The information provided is tailored to the needs of each individual enquirer giving them greater access to cancer support and information which complements the service provided by the clinical teams in hospitals or in the community. In 2018 there were 47371 contacts to the service.
Methods
Impact Monitoring uses surveys (paper and online) to collect information from service users. The nurses recruited cancer support enquirers over a two month period during September and October 2018. An enquirers’ distress level was assessed (using distress screening) by the nurse to determine if they were suitable to take part in the survey. Consent was obtained from participants across all services. Returned surveys were entered into a database and analysed according to themes and patterns. All respondents were anonymous.
Results
CIS had many positive impacts. Enquirers to the service appreciated the opportunity to access information from a healthcare professional either by phone or within a Daffodil Centre. During analysis some of the main benefits of the service identified include • Increased knowledge of cancer and its symptoms • More supported and aware of emotional supports • More in control • Reduced anxiety. Accurate and reliable information from a CIS healthcare professional offered reassurance to patients.
Conclusions
Having access to a cancer nurse through the CIS gave cancer patients the opportunity to avail of support, information and advice as and when they needed it. Enquirers felt they could talk through their questions and concerns, with the nurse providing information and guidance which reassured them. Talking to a nurse helped people feel more supported, more knowledgeable about their cancer and hopeful about the future.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2436 - Development and Validation of an RNA-Seq Assay for Gene Fusions Detection in Formalin-Fixed Paraffin-Embedded Samples
Presenter: Hua Dong
Session: Poster Display session 3
Resources:
Abstract
5271 - A Pilot Study to Implement an Artificial Intelligence (AI) System for Gastrointestinal Cancer Clinical Trial Matching
Presenter: Zhaohui Jin
Session: Poster Display session 3
Resources:
Abstract
4787 - A Blinded Comparison of Patient Treatments to Therapeutic Options Presented by an Artificial Intelligence-based Clinical Decision-support system
Presenter: Suthida Suwanvecho
Session: Poster Display session 3
Resources:
Abstract
5744 - OncOS: scalable and accurate next-generation sequencing analytics for precision oncology and personalized patient care
Presenter: Joe Thompson
Session: Poster Display session 3
Resources:
Abstract
3752 - The association between wearable device physical activity metrics and performance status in oncology: a systematic review
Presenter: Milan Kos
Session: Poster Display session 3
Resources:
Abstract
5820 - SomaticNET: neural network evaluation of somatic mutations in cancer
Presenter: Geoffroy Dubourg-Felonneau
Session: Poster Display session 3
Resources:
Abstract
4771 - Is there a role for Next-generation sequencing (NGS) profiling on metastatic non-colorectal gastrointestinal carcinomas (MNCGIC) in developing countries? A single center experience.
Presenter: Mauricio Ribeiro
Session: Poster Display session 3
Resources:
Abstract
1209 - Metastatic Cancer Whole-Exome Sequencing in daily practice
Presenter: Manon Réda
Session: Poster Display session 3
Resources:
Abstract
5702 - Genomic-Guided Individualized Precision Therapy in Refractory Metastatic Solid Tumor Patients with Extensively Poor Performance Status: A Chinese single institutional prospective observational real-world study
Presenter: Haitao Wang
Session: Poster Display session 3
Resources:
Abstract
4021 - Prospective pathological experience with research biopsies in the context of clinical trials at Vall d’Hebron Institute of Oncology
Presenter: Paolo Nuciforo
Session: Poster Display session 3
Resources:
Abstract